Resolution of cisplatin-induced fatigue does not require endogenous interleukin-10 in male mice.
Academic Article
Overview
Research
Identity
Additional Document Info
Other
View All
Overview
abstract
Based on previous results showing a pivotal role of endogenous interleukin-10 (IL-10) in the recovery from cisplatin-induced peripheral neuropathy, the present experiments were carried out to determine whether this cytokine plays any role in the recovery from cisplatin-induced fatigue in male mice. Fatigue was measured by decreased voluntary wheel running in mice trained to run in a wheel in response to cisplatin. Mice were treated with a monoclonal neutralizing antibody (IL-10na) administered intranasally during the recovery period to neutralize endogenous IL-10. In the first experiment, mice were treated with cisplatin (2.83mg/kg/day) for five days and IL-10na (12g/day for three days) five days later. In the second experiment, they were treated with cisplatin (2.3mg/kg/day for 5 days twice at a five-day interval) and IL10na (12g/day for three days) immediately after the last injection of cisplatin. In both experiments, cisplatin decreased body weight and reduced voluntary wheel running. However, IL-10na did not impair recovery from these effects. These results show that the recovery from the cisplatin-induced decrease in wheel running does not require endogenous IL-10 in contrast to the recovery from cisplatin-induced peripheral neuropathy.
